Similar articles

Abstract: Objective: To investigate the in-vitro antitumor immune responses of dendritoma formed by mouse hepatocellular carcinoma (HCC) cells and lymphotactin (Lptn) gene modified dendritic cells (DCs). Method: DCs prepared from mouse bone marrow were genetically modified by lymphotactin adenovirus, and fused with H22 cells by polyethylene glycol (PEG). RT-PCR and ELISA were employed to identify lymphotactin expression at mRNA and protein level. Cell phenotypes and fusion efficiency was detected by FACS. The stimulatory effect of DC on T cells was detected by mixed lymphocyte reaction. The cytotoxicity activity against H22 cells was assayed by LDH method. Results: lymphotactin could be efficiently expressed by DCLptn/H22 hybridoma. DCLptn/H22 cells could induce potent T cell proliferation effect and generate strong cytotoxic T lymphocyte (CTL) reaction against allogenic H22 cells. Conclusion: lymphotactin genetic modification could enhance the in vitro immune activity of the dendritoma.

[1] Banchereau, J., Steinman, R.M., 1998. Dendritic cells and the control of immunity. Nature, 392(6673):245-252.

[2] Cao, X., Zhang, W., He, L., Xie, Z., Ma, S., Tao, Q., Yu, Y., Hamada, H., Wang, J., 1998. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. Journal of Immunology, 161(11):6238-44.

[3] Emtage, P.C., Xing, Z., Wan, Y., Zlotnik, A., Graham, F.L., Gauldie, J., 2002. Adenoviral-mediated gene transfer of lymphotactin to the lungs of mice and rats results in infiltration and direct accumulation of CD4⁺, CD8⁺, and NK cells. Journal of Interferon & Cytokine Research, 22(5):573-582.

[4] Gong, J., Koido, S., Chen, D., Tanaka, Y., Huang, L., Avigan, D., Anderson, K., Ohno, T., Kufe, D., 2002. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood, 99(7):2512-2517.

[5] Homma, S., Toda, G., Gong, J., Kufe, D., Ohno, T., 2001. Preventive antitumor activity against hepatocellular carcinoma induced by immunization with fusions of dendritic cells and HCC cells in mice. Journal of Gastroenterology, 36(11):764-771.

[6] Huang, H., Li, F., Gordon, F.R., Xiang, J., 2002. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4⁺ and CD8⁺ T cells and intratumoral lymphotactin transgene expression. Cancer Research, 62(4):2043-2051.

[7] Kurt, R.A., Bauck, M., Harma, S., McCulloch, K., Baher, A., Urba, W.J., 2001. Role of C chemokine lymphotactin in mediating recruitment of antigen-specific CD62L (lo) cells in vitro and in vivo. Cellular Immunology, 209(2):83-88.

[8] Moingeon, P., 2001. Cancer vaccines. Vaccine, 19(11-12):1305-1326.

[9] Soruri, A., Fayyazi, A., Neumann, C., Schlott, T., Jung, T., Mrtthes, C., Zwirner, J., Riggert, J., Peters, J.H., 2001. Ex vivo generation of human anti-melanoma autologous cytolytic T cells by dendritic cell/melanoma cell hybridimas. Cancer Immunology Immunotherapy, 50(6):307-314.

[10] Wang, J., Saffold, S., Cao, X., Krauss, J., Chen, W., 1998. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Journal of Immunology, 161(10):5516-5524.

[11] Yoshida, T., Izawa, D., Nakayama, T., Nakahara, K., Kazizaki, M., Imai, T., Suzuki, R., Miyasaka, M., Yoshie, D., 1999. Molecular cloning of mXCR1, the murine SCM-1/lymphotactin receptor. FEBS Letters, 458(1):37-40.